Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...